Eli Cas­din backs Codex­is' plat­form tech with $50M eq­ui­ty buy

4 days ago
People
Venture

In­vestors pony up $476M for the lat­est round of biotech IPOs to hit the Street

4 days ago
IPOs

Ve­rastem CEO For­rester steps to the ex­it as the board hunts com­mer­cial-savvy ex­ec for the be­lea­guered biotech

4 days ago
People

Who’s next in line to suc­ceed Ken Fra­zier as CEO of the Keytru­da-blessed Mer­ck?

4 days ago
People

In starved an­tibi­ot­ic field, Melin­ta soars as FDA grants speedy drug re­view

4 days ago
Pharma
R&D

An­a­lyst call with Al­ler­gan ex­ecs stokes an­tic­i­pa­tion of a plan to split the com­pa­ny in ‘a month or two’

4 days ago
Deals
Pharma

Sanofi's John Reed con­tin­ues to re­or­ga­nize R&D, cut­ting 466 jobs while boost­ing can­cer, gene ther­a­py re­search

5 days ago
R&D

Arc­turus ex­pands col­lab­o­ra­tion, adding $30M cash; Ku­ra shoots for $100M raise

5 days ago
Protocols

Chica­go biotech ar­gues blue­bird, Third Rock 'killed' its ri­val, pi­o­neer­ing tha­lassemia gene ther­a­py in law­suit

5 days ago
People
Pharma

Wood­ford braces po­lit­i­cal storm as UK fi­nan­cial reg­u­la­tors scru­ti­nize fund sus­pen­sion

5 days ago
People
Venture

New study ques­tions the need for 12 years of mar­ket ex­clu­siv­i­ty for bi­o­log­ics

5 days ago
Regulatory

Gilead baits new al­liance with $45M up­front, div­ing in­to the busy pro­tein degra­da­tion field

5 days ago
Deals

A new num­ber 1 drug? Keytru­da tapped to top the 10 biggest block­busters on the world stage by 2024

5 days ago
Pharma

Iron­wood, Al­ler­gan add a slate of PhI­I­Ib da­ta to its Linzess pitch for physi­cians, pa­tients

5 days ago
Pharma

In­vestor day prep at Mer­ck in­cludes a new strat­e­gy to pick up the pace on M&A — re­port

5 days ago
Deals
R&D

Bob Langer's first port of call — Po­laris Part­ners — maps $400M for ninth fund

5 days ago
Venture

'It's a growth play': Catal­ent ac­quires Bris­tol-My­er­s' Eu­ro­pean launch pad, ex­pand­ing glob­al CD­MO ops

5 days ago
Deals
Outsourcing

Pre­clin­i­cal an­ti­sense biotech, led by for­mer Sarep­ta CEO Kaye, vaults on to Nas­daq with up­sized IPO

5 days ago
IPOs

David de Graaf now has his $28.5M launch round in place, build­ing a coen­zyme A plat­form in his lat­est start­up

5 days ago
Startups
Venture

Uni­ty's ear­ly longevi­ty da­ta look 'en­cour­ag­ing'; Adap­tive Biotech­nolo­gies looks to raise $200M in IPO

6 days ago
Protocols

Study: Just half of post­mar­ket­ing com­mit­ment tri­als are pub­lished

6 days ago
R&D
Regulatory

Right back at you, Pfiz­er: BeiGene and a Pfiz­er spin­out launch a new­co to de­vel­op a MEK/BRAF in­hibitor that could ri­val $11.4B com­bo

6 days ago
R&D

Step­ping on Roche's toes, Mer­ck cuts in­to SCLC niche with third-line Keytru­da OK

6 days ago
Pharma

Sanofi aligns it­self with Google to stream­line drug de­vel­op­ment

6 days ago
Deals
R&D
First page Previous page 12345 Next page Last page